Cholesterol-lowering drugs and Alzheimer's disease

Gunter P. Eckert, Walter E. Müller, W. Gibson Wood

Research output: Contribution to journalReview article

13 Scopus citations

Abstract

Experimental in vitro and in vivo findings as well as some retrospective epidemiological studies link cholesterol homeostasis with Alzheimer's disease (AD), and there are some reports suggesting that statins may be efficacious in preventing or treating AD. In vivo and in vitro studies demonstrate that modiffication of cholesterol levels alters amyloid precursor protein and amyloid β peptide (Aβ) levels but the majority of human data on serum and brain cholesterol levels do not support a role of cholesterol in AD. Moreover, the initial epidemiological reports on statins and AD may have overestimated the extent of protection, since prospective studies and recent meta-analyses show little, if any, support for the efficacy of statins in dementia. This brief but focused review examines support for and against the hypothesis that cholesterol is Involved in AD and addresses the issue as to whether statins should be considered for the prevention and treatment of AD.

Original languageEnglish (US)
Pages (from-to)423-432
Number of pages10
JournalFuture Lipidology
Volume2
Issue number4
DOIs
StatePublished - Aug 1 2007

Keywords

  • Alzheimer's disease
  • Brain
  • Cholesterol
  • Statins

Fingerprint Dive into the research topics of 'Cholesterol-lowering drugs and Alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this

    Eckert, G. P., Müller, W. E., & Wood, W. G. (2007). Cholesterol-lowering drugs and Alzheimer's disease. Future Lipidology, 2(4), 423-432. https://doi.org/10.2217/17460875.2.4.423